• Publications
  • Influence
The kallikrein-kinin system: current and future pharmacological targets.
The main properties of this kallikrein-kinin system are summarized and the multiple pharmacological interventions that modulate the functions of this system, restraining its proinflammatory effects or potentiating its cardiovascular properties are addressed. Expand
Angiotensin-converting enzyme inhibitor-associated angioedema.
The remitting and relapsing nature of ACE inhibitor-associated angioedema can confound clinical recognition of the adverse event but also provides clues to its causes. Expand
Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors
The data suggest that low plasma concentrations of aminopeptidase P could be a predisposing factor for development of angio-oedema in patients treated with ACE inhibitors. Expand
The kallikrein-kininogen-kinin system: lessons from the quantification of endogenous kinins
The purpose of the present review is to review and compare the different analytical methods reported for the assessment of endogenous kinins, to explain the difficulties and the pitfalls for their quantifications in biologic samples and to see how the results obtained by these methods could complement and extend the pharmacological evidence of their pathophysiological role. Expand
Bradykinin and des-Arg(9)-bradykinin metabolic pathways and kinetics of activation of human plasma.
  • M. Cyr, Y. Lepage, +4 authors A. Adam
  • Chemistry, Medicine
  • American journal of physiology. Heart and…
  • 1 July 2001
A mathematical model applied to the BK kinetically released from endogenous high-molecular-weight kininogen during plasma activation in the presence of an ACE inhibitor revealed a significant difference in the rate of formation of BK between men and women, forming a basis for future pathophysiological studies of inflammatory processes where activation of the contact system of plasma and the kinins is involved. Expand
A variant in XPNPEP2 is associated with angioedema induced by angiotensin I-converting enzyme inhibitors.
Supporting evidence is provided that the C-2399A variant in XPNPEP2 is associated with reduced APP activity and a higher incidence of AE-ACEi, a potentially life-threatening adverse reaction known as angioedema. Expand
Angiotensin-Converting Enzyme Inhibitor-Associated Angioedema Is Characterized by a Slower Degradation of des-Arginine9-Bradykinin
It is shown, for the first time, that an abnormality of endogenous des-Arg9-BK degradation exists in the plasma of patients with ACEi-associated AE, suggesting that its pathogenetic mechanism lies in the catabolic site of kinin metabolism. Expand
Dipeptidyl Peptidase IV in Angiotensin-Converting Enzyme Inhibitor–Associated Angioedema
This case-control study tested the hypothesis that dipeptidyl peptidase IV activity and antigen are decreased in sera of patients with a history of angiotensin-converting enzyme inhibitor–associated angioedema, and found that it was true. Expand
Kinin receptors: functional aspects.
Two types of receptors (B1R, B2R) for kinins are defined in mammalian species. Comparative experiments involving recombinant fusion proteins consisting of rabbit B1R or B2R fused to GFP-relatedExpand
Increase in blood bradykinin concentration after eccentric weight-training exercise in men.
The observation that BK concentration significantly increased immediately after the exercise session suggests that the inflammatory process due to eccentric exercise-induced muscle damage could be mediated in part by BK. Expand